228 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
2 Terminated A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
Condition: Cancer, Metastatic
Interventions: Drug: Carboplatin;   Drug: Pazopanib
3 Recruiting Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Condition: Multiple Myeloma
Intervention:
4 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
5 Completed Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
Condition: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions: Drug: AZD1775;   Drug: AZD1775 Matching Placebo;   Drug: pemetrexed;   Drug: carboplatin
6 Not yet recruiting Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Conditions: Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
7 Recruiting Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
Condition: Hematological Diseases
Intervention: Drug: Allogeneic transplant conditioning
8 Not yet recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Radiation: indium In 111-DOTA-biotin;   Radiation: yttrium Y 90 DOTA-biotin;   Drug: Clearing Agent;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
9 Not yet recruiting TIL Therapy for Metastatic Ovarian Cancer
Condition: Metastatic Ovarian Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL infusion;   Drug: Interleukin-2
10 Not yet recruiting Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
11 Recruiting Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation
Condition: Small Cell Lung Cancer Recurrent
Intervention: Drug: Temozolomide
12 Not yet recruiting Study of Bendamustine and Ixazomib (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Bendamustine
13 Recruiting Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ACP-196;   Drug: Obinutuzumab;   Drug: Chlorambucil
14 Completed Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
15 Recruiting Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
Condition: Liver Dysfunction
Intervention: Drug: Mivacurium Chloride
16 Recruiting Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
Condition: EWINGS SARCOMA
Interventions: Drug: Rabbit anti-thymocyte globulin;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide
17 Not yet recruiting KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Conditions: Burkitt's Lymphoma (BL);   B-Cell Lymphoma
Interventions: Drug: KPT-330;   Drug: Rituximab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Dexamethasone
18 Not yet recruiting Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT
Condition: Transitional Cell Carcinoma
Intervention: Other: BWT with Mitomycin-C prior TURBT
19 Recruiting Ruxolitinib in Combination With Autotransplant
Conditions: Myelofibrosis;   MF
Interventions: Drug: RUXOLITINIB / INC 424;   Drug: Filgrastim;   Drug: Busulfan
20 Recruiting Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer
Condition: Breast Cancer
Interventions: Drug: EC-T or TC plus GM1;   Drug: EC-T or TC plus placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years